CG Oncology vs Lantheus Holdings

CG Oncology (CGON), health care, and Lantheus Holdings (LNTH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

CG Oncology is worth $7.1B on the stock market and Lantheus Holdings $6.7B: CG Oncology is valued at 6% more. CG Oncology's operating margin in its latest fiscal year was -4722% and Lantheus Holdings's 20.2%. Over the past year CG Oncology's share price has moved +99.2% and Lantheus Holdings's +90.1%.

Key facts

CG Oncology market value
$7.1B
Lantheus Holdings market value
$6.7B
Lantheus Holdings P/E
25.3
CG Oncology revenue
$4MFY to 2025-12-31
Lantheus Holdings revenue
$1.5BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

CG Oncology vs Lantheus Holdings: every measure side by side
Measure CG Oncology Lantheus Holdings
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.1Bhigher$6.7Blower
Revenue$4Mlower$1.5Bhigher
Earnings-$161Mlower$233.6Mhigher
Employees142lower1,193higher
Total assets$791.6Mlower$2.2Bhigher
Valuation
P/E—25.3
P/S1745higher4.3lower
P/B7.1higher4.9lower
Dividend yield0.00%0.00%
Profitability
Operating margin-4722%lower20.2%higher
Balance sheet
Net assets$752.6Mlower$1.1Bhigher
Total liabilities$39Mlower$1.1Bhigher
Total debt$3Mlower$569.4Mhigher
Cash on hand$32.5Mlower$359.1Mhigher
Price change
Today-6.89%lower+0.08%higher
1 year+99.2%higher+90.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

CG Oncology only (0)

None of the tracked investors.

Lantheus Holdings only (2)

Percentages are each holding's share of that investor's reported portfolio. · Who owns LNTH

Further comparisons

Learn

Questions and answers

Which is bigger, CG Oncology or Lantheus Holdings?

By market value, CG Oncology is the larger: $7.1B against $6.7B for Lantheus Holdings. By revenue in its latest fiscal year, Lantheus Holdings is the larger: $1.5B against $4M for CG Oncology.

Which has the higher operating margin?

Lantheus Holdings: 20.2%, against -4722% for CG Oncology. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Lantheus Holdings: $569.4M, against $3M for CG Oncology. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both CG Oncology and Lantheus Holdings?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold CG Oncology and 2 hold Lantheus Holdings.

Cite this page

Funkfolio, “CG Oncology vs Lantheus Holdings”, data as of 17 November 2026. https://funkfolio.com/compare/cgon-vs-lnth

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.